News
Preclinical insights into dosing for first-in-human in vivo liver-directed gene therapy for MMA delivered in an oral presentation at the ASGCT Annual Meeting
Milan, 31 March 2025
The AstraZeneca acquisition of EsoBiotec – important validation for Genespire’s lentiviral vector platform
Milan, 25 September 2024
Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic
Milan, 12 September 2024
Genespire appoints Karen Aiach-Pignet as Chief Executive Officer
Milan, 9 May 2024
Genespire Presents Positive Preclinical Proof of Concept Data at the ASGCT Annual Meeting
Milan, 7 July 2022
Genespire appoints Dr. Sabah Sallah as Chief Medical Officer
Milan, 13 July 2021
Genespire appoints Phillippe Mauberna as Chief Financial Officer
Milan, May 5, 2021
Genespire Strengthens Management Team with Two Key Appointments
Milan, July 30, 2020
Genespire appoints Jörn Aldag as Chairman of the Board of Directors
Milan, June 30, 2020
Genespire and the San Raffaele Telethon Institute for Gene Therapy announce publication in Nature Biotechnology on enhanced gene editing technique in hematopoietic stem cells
Milan, May 13, 2020
Genespire and SR-Tiget announce strategic alliance for the development of transformative gene therapies for genetic diseases and disclose collaboration focus
Milan, April 29, 2020
Genespire Secures €16 Million Series A Financing from Sofinnova Partners to Advance Transformative Gene Therapies